Skip to content

Journal · Drug therapy · Updated 21 November 2026

Drugs & Therapy Perspectives

Read Drugs & Therapy Perspectives articles on DeepDyve. No university library needed.

Drugs & Therapy Perspectives has published since 1993 and covers how medicines are used in practice, from profiles of newly approved drugs for dry eye disease and acute pain to shorter antibiotic courses for children with pneumonia and influenza care for older adults. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Drugs & Therapy Perspectives
Journal cover

Drugs & Therapy Perspectives at a glance

Full title
Drugs & Therapy Perspectives
Abbreviation (NLM)
Drugs Ther Perspect
Publisher
Springer Nature
Print ISSN
1172-0360
Online ISSN (eISSN)
1179-1977
First published
1993
Access model
Open access since 2026

Ways to access Drugs & Therapy Perspectives

All of the articles Drugs & Therapy Perspectives published from January 1 to November 19, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 100% of Drugs & Therapy Perspectives articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Drugs & Therapy Perspectives. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Drugs & Therapy Perspectives articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Drugs & Therapy Perspectives’ 2025 Journal Impact Factor is 0.6, and its 5-year Impact Factor is 0.6.

0.6

Journal Impact Factor (2025)

0.6

5-year Impact Factor (2025)

8 days

Median time to first decision

Source: journal metrics on the Drugs & Therapy Perspectives homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Drugs & Therapy Perspectives research worth reading

Published February to April 2026. Summaries describe what the authors report.

  1. Open accessPediatrics · Antibiotics

    Short-course antibiotics can be just as effective for community-acquired pneumonia in children

    The author reports emerging evidence that a 3–5 day course of oral antibiotics cures bacterial community-acquired pneumonia in children as well as 5–10 day courses, but notes the data mainly cover non-severe outpatient cases and more research may be needed before guidelines change.

    Kang · Drugs & Therapy Perspectives, published online February 9, 2026 · DOI 10.1007/s40267-026-01218-z

  2. Open accessOphthalmology · Dry eye disease

    Acoltremon 0.003% ophthalmic solution in dry eye disease: a profile of its use

    The authors profile acoltremon 0.003%, a TRPM8 thermoreceptor agonist eye drop approved in the USA for dry eye disease, reporting that it significantly improved tear production from day 1 in two phase 3 trials and was well tolerated.

    Chen et al. · Drugs & Therapy Perspectives, published online April 6, 2026 · DOI 10.1007/s40267-026-01232-1

  3. Open accessEpilepsy · SUDEP

    Reduce tonic-clonic seizures with antiseizure medications to lower the risk of sudden unexpected death in epilepsy

    The authors report that the frequency of tonic-clonic seizures is the greatest risk factor for sudden unexpected death in epilepsy, so reducing seizures with antiseizure medications is key, alongside medication adherence and nighttime supervision or seizure detection devices.

    Chen et al. · Drugs & Therapy Perspectives, published online February 9, 2026 · DOI 10.1007/s40267-026-01221-4

  4. Open accessPain medicine · Non-opioid analgesics

    Suzetrigine in moderate to severe acute pain: a profile of its use

    The authors profile suzetrigine, a NaV1.8 inhibitor approved in the USA for moderate to severe acute pain, reporting that it reduced pain more than placebo in two phase 3 trials but was not shown superior to hydrocodone bitartrate/acetaminophen.

    McGuigan et al. · Drugs & Therapy Perspectives, published online March 10, 2026 · DOI 10.1007/s40267-026-01216-1

  5. Open accessInfluenza · Older adults

    Protect older adults from influenza with vaccination and early antivirals

    The authors report that guidance on managing influenza in adults aged 65 and over is extremely limited, that consensus favors prevention through vaccination, and that antivirals should start as soon as possible for severe or high-risk cases.

    Burgess et al. · Drugs & Therapy Perspectives, published online March 24, 2026 · DOI 10.1007/s40267-026-01228-x

See every Drugs & Therapy Perspectives article on DeepDyve

Questions about Drugs & Therapy Perspectives

How can I read Drugs & Therapy Perspectives articles without a subscription?

100% of Drugs & Therapy Perspectives articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Drugs & Therapy Perspectives articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Drugs & Therapy Perspectives?

Drugs & Therapy Perspectives’ NLM (PubMed) abbreviation is Drugs Ther Perspect.

What is the ISSN of Drugs & Therapy Perspectives?

The print ISSN is 1172-0360 and the online ISSN is 1179-1977.

What is the impact factor of Drugs & Therapy Perspectives?

Drugs & Therapy Perspectives’ Journal Impact Factor is 0.6 (2025), and its 5-year Impact Factor is 0.6, according to Springer Nature’s published metrics.

Is Drugs & Therapy Perspectives open access?

Yes. Drugs & Therapy Perspectives has published open access since 2026: 69 of the 69 articles it published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref.

Drugs & Therapy Perspectives articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Drugs & Therapy Perspectives today

One month free, then less than $2 a day. Drugs & Therapy Perspectives, plus millions of articles from thousands of journals.

Start free month

Like this: